Patients allocated to group B who achieved RVR continued on RBV ( @mg/day ) for a further @ weeks ( B@ ; n = @ ) while non-RVR patients received a higher dose of RBV ( @ mg/day ) + epoetin ( B@ ; n = @ ) .